CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

NCT03699319 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: CPI 613
DRUG: Oxaliplatin
DRUG: Irinotecan
DRUG: 5-flurouracil
DRUG: Folinic acid

Sponsor

David Bajor, MD